<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin Med J (Engl)</journal-id><journal-id journal-id-type="iso-abbrev">Chin. Med. J</journal-id><journal-id journal-id-type="publisher-id">CMJ</journal-id><journal-title-group><journal-title>Chinese Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">0366-6999</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25591555</article-id><article-id pub-id-type="pmc">4837831</article-id><article-id pub-id-type="publisher-id">CMJ-128-153</article-id><article-id pub-id-type="doi">10.4103/0366-6999.149185</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Valsartan Decreases Platelet Activity and Arterial Thrombotic Events in Elderly Patients with Hypertension</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Fang</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Hong-Yan</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Fan</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Ling-Jie</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Feng-Ru</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xiao-Nan</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Qian</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Meng-Hui</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xue-Feng</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Wei-Feng</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Geriatrics, Ruijin Hospital, Jiao Tong University School of Medicine, Shanghai 200025, China</aff><aff id="aff2"><label>2</label>Department of Cardiology, Ruijin Hospital, Jiao Tong University School of Medicine, Shanghai 200025, China</aff><aff id="aff3"><label>3</label>Institute of Health Sciences, Jiao Tong University School of Medicine and Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200025, China</aff><aff id="aff4"><label>4</label>Department of Laboratory Medicine, Ruijin Hospital, Jiao Tong University School of Medicine, Shanghai 200025, China</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Wei-Feng Shen, Department of Cardiology, Ruijin Hospital, Jiao Tong University School of Medicine, Shanghai 200025, China E-mail: <email xlink:href="rjshenweifeng@126.com">rjshenweifeng@126.com</email></corresp></author-notes><pub-date pub-type="ppub"><day>20</day><month>1</month><year>2015</year></pub-date><volume>128</volume><issue>2</issue><fpage>153</fpage><lpage>158</lpage><history><date date-type="received"><day>09</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2015 Chinese Medical Journal</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Angiotensin type 1 receptor (AT<sup>1</sup>R) antagonists are extensively used for blood pressure control in elderly patients with hypertension. This study aimed to investigate the inhibitory effects of AT<sub>1</sub>R antagonist valsartan on platelet aggregation and the occurrence of cardio-cerebral thrombotic events in elderly patients with hypertension.</p></sec><sec id="st2"><title>Methods:</title><p>Two-hundred and ten patients with hypertension and aged &#x0003e; 60 years were randomized to valsartan (<italic>n</italic> = 140) or amlodipine (<italic>n</italic> = 70) on admission. The primary endpoint was platelet aggregation rate (PAR) induced by arachidonic acid at discharge, and the secondary endpoint was the rate of thrombotic events including brain infarction and myocardial infarction during follow-up. Human aortic endothelial cells (HAECs) were stimulated by angiotensin II (Ang II, 100 nmol/L) with or without pretreatment of valsartan (100 nmol/L), and relative expression of cyclooxygenase-2 (COX-2) and thromboxane B<sub>2</sub> (TXB<sub>2</sub>) and both p38 mitogen-activated protein kinase (p38MAPK) and nuclear factor-kB (NF-kB) activities were assessed. Statistical analyses were performed by GraphPad Prism 5.0 software (GraphPad Software, Inc., California, USA).</p></sec><sec id="st3"><title>Results:</title><p>PAR was lower after treatment with valsartan (11.49 &#x000b1; 0.69% vs. 18.71 &#x000b1; 2.47%, <italic>P</italic> &#x0003c; 0.001), associated with more reduced plasma levels of COX-2 (76.94 &#x000b1; 7.07 U/L vs. 116.4 &#x000b1; 15.89 U/L, <italic>P</italic> &#x0003c; 0.001) and TXB<sub>2</sub> (1667 &#x000b1; 56.50 pg/ml vs. 2207 &#x000b1; 180.20 pg/ml) (all <italic>P</italic> &#x0003c; 0.001). Plasma COX-2 and TXB<sub>2</sub> levels correlated significantly with PAR in overall patients (<italic>r</italic> = 0.109, <italic>P</italic> &#x0003c; 0.001). During follow-up (median, 18 months), there was a significantly lower thrombotic event rate in patients treated with valsartan (14.3% vs. 32.8%, <italic>P</italic> = 0.002). Relative expression of COX-2 and secretion of TXB<sub>2</sub> with concordant phosphorylation of p38MAPK and NF-kB were increased in HAECs when stimulated by Ang II (100 nmol/L) but were significantly decreased by valsartan pretreatment (100 nmol/L).</p></sec><sec id="st4"><title>Conclusions:</title><p>AT<sub>1</sub>R antagonist valsartan decreases platelet activity by attenuating COX-2/TXA<sub>2</sub> expression through p38MAPK and NF-kB pathways and reduces the occurrence of cardio-cerebral thrombotic events in elderly patients with hypertension.</p></sec></abstract><kwd-group><kwd>Angiotensin Type 1 Receptor Antagonist</kwd><kwd>Elderly</kwd><kwd>Hypertension</kwd><kwd>Platelet Activity</kwd><kwd>Thrombosis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>I<sc>NTRODUCTION</sc></title><p>A large body of evidence has demonstrated that activation of renin-angiotensin system (RAS) plays a key role in the development and progression of hypertension and cardiovascular disease.[<xref rid="ref1" ref-type="bibr">1</xref>] Angiotensin II (Ang II), the major effector of RAS,[<xref rid="ref2" ref-type="bibr">2</xref>] exerts its biological effects mainly through specific receptors, namely angiotensin type 1 receptor (AT<sub>1</sub>R) and type 2 receptor.[<xref rid="ref3" ref-type="bibr">3</xref>] Since AT<sub>1</sub>R antagonists have been shown to improve endothelial function and vascular remodeling in addition to their predominant vasodilatation effects,[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>] these agents are extensively used for blood pressure control in elderly patients with hypertension.[<xref rid="ref6" ref-type="bibr">6</xref>]</p><p>Activation of platelets bears the brunt of complicate cascades of thrombogenesis. Among the physiological activators of platelet, thromboxane A<sub>2</sub> (TXA<sub>2</sub>) is the primary one which is conversed from arachidonic acid in the platelets and catalyzed by cyclooxygenase (COX).[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref>] TXA<sub>2</sub> is regulated by two isoforms of COX. COX-1 is usually found in the physical condition, whereas COX-2 is induced by lipopolysaccharide and some cytokines.[<xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref>] Clinical studies have demonstrated a close relationship between plasma levels of TXA<sub>2</sub> or COX-2 and platelet activities.[<xref rid="ref13" ref-type="bibr">13</xref>] AT<sub>1</sub>R antagonists are known to exhibit potent anti-platelet properties which may differ from other anti-platelet agents.[<xref rid="ref14" ref-type="bibr">14</xref>] However, the impact of these agents on arterial thrombotic events in elderly patients with hypertension remains largely unclear.</p><p>In this randomized trial, we assessed the effect of valsartan-an AT<sub>1</sub>R antagonist on platelet aggregation rate (PAR) and the occurrence of cardio-cerebral thrombotic events including brain and myocardial infarction in hypertensive patients aged &#x0003e;60 years. To further elucidate the potential mechanisms of its anti-platelet property, relative expression of COX-2 and TXB<sub>2</sub> and p38 mitogen-activated protein kinase (p38MAPK) and nuclear factor-kB (NF-kB) activities in human aortic endothelial cells (HAECs) stimulated by Ang II with or without pretreatment of valsartan were also determined.</p></sec><sec sec-type="methods" id="sec1-2"><title>M<sc>ETHODS</sc></title><sec id="sec2-1"><title>Study population</title><p>Two hundred and thirty-six consecutive elderly (&#x0003e;60 years in age) patients with hypertension who were admitted to the Department of Geriatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine between April 2011 and August 2013 were screened. Hypertension was diagnosed as systolic blood pressure &#x02265;140 mmHg and/or diastolic pressure &#x02265;90 mmHg before recruitment.[<xref rid="ref15" ref-type="bibr">15</xref>] For the purpose of research, patients with acute or chronic infection, hepatic or at least moderate renal insufficiency (estimated glomerular filtration rate [eGFR] &#x0003c;60 ml&#x00387;min<sup>-1</sup>&#x00387;1.73 m<sup>-2</sup>) (<italic>n</italic> = 17), trauma or surgery within 2 months (<italic>n</italic> = 2), and other blood diseases (e.g. hemophilia, and leukemia, aplastic anemia) (<italic>n</italic> = 5) were excluded. We also excluded patients with resistant hypertension (<italic>n</italic> = 2).[<xref rid="ref16" ref-type="bibr">16</xref>] The remaining 210 eligible elderly hypertensive patients (191 men and 19 women, mean age 79.2 &#x000b1; 1.0 years) were randomized to valsartan (Beijing Novartis Pharma Ltd., China) (AT<sub>1</sub>R group; <italic>n</italic> = 140) or amlodipine (Beijing Novartis Pharma Ltd.) (non-AT<sub>1</sub>R group; <italic>n</italic> = 70) in a 2:1 ratio [<xref ref-type="fig" rid="F1">Figure 1</xref>] by random group design. For each group, the initial dose of valsartan (80 mg, once daily) or amlordipine (5 mg, once daily) was titrated to achieve target blood pressure (&#x0003c;140/90 mmHg for patients under 80 years and &#x0003c; 150/90 mmHg for those older than 80 years). A small dose of diuretics like hydrochlorothiazide (Shanghai Xinyi Pharma Ltd., China) (12.5&#x02013;25 mg, once daily) may be added if maximum daily dose of valsartan (160 mg) or amlodipine (10 mg) was insufficient for optimal blood pressure control. Other medications including &#x003b2;-blockers, anti-platelet agents, and statins were prescribed at the discretion of the physicians.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Flowchart of patient enrollment.</p></caption><graphic xlink:href="CMJ-128-153-g001"/></fig><p>The study protocol was approved by the Ethics Review Committees of Shanghai Jiao Tong University and Ruijin Hospital, and informed consent was given by each subject.</p></sec><sec id="sec2-2"><title>Biochemical investigation</title><p>Platelets aggregation in platelet-rich plasma was tested at discharge among the patients. Light transmission aggregometry through Chrono-Log platelet aggregometer (Chrono-Log Corp., USA) induced by 0.5 &#x003bc;mol/L arachidonic acid described previously.[<xref rid="ref17" ref-type="bibr">17</xref>] Plasma levels of COX-2 (MyBiosource, USA) and TXA<sub>2</sub> (Enzo Life Sciences, USA) were determined by ELISA. TXA<sub>2</sub> were represented by its metabolite TXB<sub>2</sub> because it is unstable in common condition.</p></sec><sec id="sec2-3"><title>Follow-up</title><p>All patients were followed-up in a special outpatient clinic or by telephone conversation with patients or their relatives every 3 months after discharge. The occurrence of arterial thrombotic events, including brain and myocardial infarctions were recorded. Brain infarction was defined by neurologic examination, head magnetic resonance imaging and/or computed tomography. Myocardial infarction was defined by the presence of typical chest pain, electrocardiographic ST-segment elevation with or without Q waves, and serum cardiac enzyme elevations at least twice the upper limit of the normal range. In order to guarantee rigorous data quality, all thrombotic events were reviewed by two experienced interventional cardiologists.</p></sec><sec id="sec2-4"><title>Cell culture</title><p>Human aortic endothelial cells were cultured in Dulbecco's Modified Eagle's Medium (Life Technologies Corporation, USA) supplemented with 10% v/v fetal bovine serum (Life Technologies Corporation) and 1% penicillin-streptomycin (Life Technologies Corporation), and incubated at 37&#x000b0;C in humidified atmosphere containing 5% CO<sub>2</sub>. Valsartan (Melonepharina, China), SB203580 (Beyotime, China), JSH-23 (Beyotime) and NS-398 (Sigma, USA) was preadded into the medium 30 min before Ang II treatment.</p></sec><sec id="sec2-5"><title>Real-time polymerase chain reaction</title><p>Total RNA prepared with RNAprep Pure Cell/Bacteria Kit (Tiangen biotech, China) was reverse transcribed to cDNA using SuperScript&#x02122; Preamplification system (TaKaRa Biotech, China). Prime used in the reaction were as follows: COX-2: 5&#x02019;-CCCACCCATGTCAAAACCGA-3&#x02019; (forward), 5&#x02019;-CCGGGTACAATCGCACTTATACT-3&#x02019; (reverse); GAPDH: 5&#x02019;-ATGGGGAAGGTGAAGGTCG-3&#x02019; (forward), 5&#x02019;-GGGGTCAT-TGATGGCAACAATA-3&#x02019; (reverse). Real time-polymerase chain reaction (7900 HT by Applied Biosystems, USA) was performed using SYBR Green Master Mix (Roche, Switzerland) with the following conditions: 94&#x000b0;C for 5 min, followed by 40 cycles at 94&#x000b0;C for 30 s and 60&#x000b0;C for 30 s. The relative gene expression between treatment and control was calculated using the 2<sup>&#x02212;&#x00394;Ct</sup> method with GAPDH as the reference gene.</p></sec><sec id="sec2-6"><title>Western blotting assay</title><p>Protein was extracted with RIPA lysis buffer (Beyotime, China), separated with 10% SDS-PAGE gel, and transferred onto nitrocellulose membrane. After blocking with 5% nonfat milk in TBST (tris-buffered saline, Tween 20), the membrane was probed with diluted primary antibodies at 4&#x000b0;C overnight. The membrane was washed 10 min for three times by TBST and then incubated with horseradish peroxidase-conjugated secondary antibody for 2 h at room temperature, washed three times again, and exposed by enhanced chemiluminescence. All antibodies were purchased from Cell Signaling Technology (USA).</p></sec><sec id="sec2-7"><title>Statistical analysis</title><p>The primary endpoint was PAR induced by arachidonic acid at discharge, and the secondary endpoint was the rate of thrombotic events including brain infarction and myocardial infarction during follow-up. All statistical analyses were performed by GraphPad Prism 5.0 software (GraphPad Software, Inc., California, USA). Student's <italic>t</italic>-test or one-way analysis of variance (ANOVA) was used for comparison of quantitative data between different groups. Chi-square test was used for comparing qualitative data. Data are expressed as mean &#x000b1; standard deviation (SD) or frequency. A two-sided <italic>P</italic> &#x0003c; 0.05 was considered to be statistically significant.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>R<sc>ESULTS</sc></title><sec id="sec2-8"><title>Baseline characteristics</title><p>Both AT<sub>1</sub>R and non-AT<sub>1</sub>R groups were well-matched with respect to age, sex, risk factors for coronary artery disease, blood pressure control, hepatic and renal function, and nonantihypertensive medications including &#x003b2;-blockers, anti-platelet agents, and statins [<xref ref-type="table" rid="T1">Table 1</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of elderly hypertensive patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variables</th><th align="center" valign="top" rowspan="1" colspan="1">AT<sub>1</sub>R group (<italic>n</italic> = 140)</th><th align="center" valign="top" rowspan="1" colspan="1">Non-AT<sub>1</sub>R group (<italic>n</italic> = 70)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender (male/female)</td><td align="center" rowspan="1" colspan="1">128/12</td><td align="center" rowspan="1" colspan="1">63/7</td><td align="center" rowspan="1" colspan="1">0.734</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">78.59 &#x000b1; 0.82</td><td align="center" rowspan="1" colspan="1">79.83 &#x000b1; 1.17</td><td align="center" rowspan="1" colspan="1">0.964</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus (<italic>n</italic>, %)</td><td align="center" rowspan="1" colspan="1">49 (35.0)</td><td align="center" rowspan="1" colspan="1">26 (37.1)</td><td align="center" rowspan="1" colspan="1">0.760</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary artery disease (<italic>n</italic>, %)</td><td align="center" rowspan="1" colspan="1">50 (35.7)</td><td align="center" rowspan="1" colspan="1">26 (37.1)</td><td align="center" rowspan="1" colspan="1">0.839</td></tr><tr><td align="left" rowspan="1" colspan="1">Transient ischemic attack (<italic>n</italic>, %)</td><td align="center" rowspan="1" colspan="1">38 (27.1)</td><td align="center" rowspan="1" colspan="1">22 (31.4)</td><td align="center" rowspan="1" colspan="1">0.420</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">130.70 &#x000b1; 1.33</td><td align="center" rowspan="1" colspan="1">127.50 &#x000b1; 1.94</td><td align="center" rowspan="1" colspan="1">0.617</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">74.45 &#x000b1; 0.55</td><td align="center" rowspan="1" colspan="1">73.23 &#x000b1; 1.12</td><td align="center" rowspan="1" colspan="1">0.345</td></tr><tr><td align="left" rowspan="1" colspan="1">White blood cell (&#x000d7;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">5.97 &#x000b1; 0.15</td><td align="center" rowspan="1" colspan="1">6.13 &#x000b1; 0.21</td><td align="center" rowspan="1" colspan="1">0.616</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelets (&#x000d7;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">196.40 &#x000b1; 3.53</td><td align="center" rowspan="1" colspan="1">203.60 &#x000b1; 8.51</td><td align="center" rowspan="1" colspan="1">0.606</td></tr><tr><td align="left" rowspan="1" colspan="1">Alanine transaminase (IU/L)</td><td align="center" rowspan="1" colspan="1">22.68 &#x000b1; 0.92</td><td align="center" rowspan="1" colspan="1">23.53 &#x000b1; 2.02</td><td align="center" rowspan="1" colspan="1">0.927</td></tr><tr><td align="left" rowspan="1" colspan="1">Aspartate aminotransferase (IU/L)</td><td align="center" rowspan="1" colspan="1">23.57 &#x000b1; 0.73</td><td align="center" rowspan="1" colspan="1">24.86 &#x000b1; 1.61</td><td align="center" rowspan="1" colspan="1">0.525</td></tr><tr><td align="left" rowspan="1" colspan="1">Alkaline phosphatase (IU/L)</td><td align="center" rowspan="1" colspan="1">56.83 &#x000b1; 1.74</td><td align="center" rowspan="1" colspan="1">56.28 &#x000b1; 1.85</td><td align="center" rowspan="1" colspan="1">0.986</td></tr><tr><td align="left" rowspan="1" colspan="1">Urea nitrogen (mmol/L)</td><td align="center" rowspan="1" colspan="1">6.18 &#x000b1; 0.25</td><td align="center" rowspan="1" colspan="1">6.07 &#x000b1; 0.41</td><td align="center" rowspan="1" colspan="1">0.759</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (&#x000b5;mol/L)</td><td align="center" rowspan="1" colspan="1">88.53 &#x000b1; 1.95</td><td align="center" rowspan="1" colspan="1">87.78 &#x000b1; 3.61</td><td align="center" rowspan="1" colspan="1">0.608</td></tr><tr><td align="left" rowspan="1" colspan="1">Uric acid (&#x000b5;mol/L)</td><td align="center" rowspan="1" colspan="1">384.60 &#x000b1; 23.41</td><td align="center" rowspan="1" colspan="1">346.10 &#x000b1; 10.65</td><td align="center" rowspan="1" colspan="1">0.189</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglyceride (mmol/L)</td><td align="center" rowspan="1" colspan="1">1.49 &#x000b1; 0.11</td><td align="center" rowspan="1" colspan="1">1.52 &#x000b1; 0.17</td><td align="center" rowspan="1" colspan="1">0.694</td></tr><tr><td align="left" rowspan="1" colspan="1">Cholesterol (mmol/L)</td><td align="center" rowspan="1" colspan="1">4.13 &#x000b1; 0.09</td><td align="center" rowspan="1" colspan="1">4.18 &#x000b1; 0.13</td><td align="center" rowspan="1" colspan="1">0.740</td></tr><tr><td align="left" rowspan="1" colspan="1">High-density lipoprotein (mmol/L)</td><td align="center" rowspan="1" colspan="1">1.31 &#x000b1; 0.03</td><td align="center" rowspan="1" colspan="1">1.20 &#x000b1; 0.04</td><td align="center" rowspan="1" colspan="1">0.260</td></tr><tr><td align="left" rowspan="1" colspan="1">Low-density lipoprotein (mmol/L)</td><td align="center" rowspan="1" colspan="1">2.37 &#x000b1; 0.07</td><td align="center" rowspan="1" colspan="1">2.52 &#x000b1; 0.11</td><td align="center" rowspan="1" colspan="1">0.159</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting blood-glucose (mmol/L)</td><td align="center" rowspan="1" colspan="1">5.18 &#x000b1; 0.09</td><td align="center" rowspan="1" colspan="1">5.37 &#x000b1; 0.17</td><td align="center" rowspan="1" colspan="1">0.122</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003b2;-blockers (%)</td><td align="center" rowspan="1" colspan="1">16 (11.4)</td><td align="center" rowspan="1" colspan="1">9 (12.9)</td><td align="center" rowspan="1" colspan="1">0.763</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-platelet (<italic>n</italic>, %)</td><td align="center" rowspan="1" colspan="1">130 (92.9)</td><td align="center" rowspan="1" colspan="1">67 (95.7)</td><td align="center" rowspan="1" colspan="1">0.418</td></tr><tr><td align="left" rowspan="1" colspan="1">Statins (<italic>n</italic>, %)</td><td align="center" rowspan="1" colspan="1">56 (40.0)</td><td align="center" rowspan="1" colspan="1">30 (42.9)</td><td align="center" rowspan="1" colspan="1">0.691</td></tr></tbody></table><table-wrap-foot><fn><p>Data are shown as mean &#x000b1; SD or frequency (%). AT<sub>1</sub>R: Angiotensin type 1 receptor; SD: Standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-9"><title>Platelets activity and plasma levels of cyclooxygenase-2 and thromboxane B2</title><p>Arachidonic acid-induced PAR and plasma levels of COX-2 and TXB<sub>2</sub> were significantly lower in the AT<sub>1</sub>R group than in the non-AT<sub>1</sub>R group (for all such comparisons, <italic>P</italic> &#x0003c; 0.001) [<xref ref-type="table" rid="T2">Table 2</xref>]. PAR correlated significantly with COX-2 (<italic>r</italic> = 0.109, <italic>P</italic> &#x0003c; 0.001) and TXB<sub>2</sub> (<italic>r</italic> = 0.070, <italic>P</italic> &#x0003c; 0.001), and COX-2 was closely related to TXB<sub>2</sub> (<italic>r</italic> = 0.251, <italic>P</italic> &#x0003c; 0.001).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Platelet aggregation rate and plasma level of COX-2 and TXB<sub>2</sub></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variables</th><th align="center" valign="top" rowspan="1" colspan="1">AT<sub>1</sub>R group (<italic>n</italic> = 140)</th><th align="center" valign="top" rowspan="1" colspan="1">Non-AT<sub>1</sub>R group (<italic>n</italic> = 70)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Platelet aggregation rate (%)</td><td align="center" rowspan="1" colspan="1">11.49 &#x000b1; 0.69</td><td align="center" rowspan="1" colspan="1">18.71 &#x000b1; 2.47</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">COX-2 (U/L)</td><td align="center" rowspan="1" colspan="1">75.94 &#x000b1; 7.07</td><td align="center" rowspan="1" colspan="1">116.4 &#x000b1; 15.89</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">TXB<sub>2</sub> (pg/ml)</td><td align="center" rowspan="1" colspan="1">1667 &#x000b1; 56.50</td><td align="center" rowspan="1" colspan="1">2207 &#x000b1; 180.20</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>Data are shown as mean &#x000b1; SD. SD: Standard deviation; AT<sub>1</sub>R: Angiotensin type 1 receptor; COX-2: Cyclooxygenase-2; TXB<sub>2</sub>: Thromboxane B<sub>2</sub>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-10"><title>Thrombotic events</title><p>During follow-up (median 18 months), 9 patients in the AT<sub>1</sub>R group and 11 in the non-AT<sub>1</sub>R group developed brain infarction (<italic>P</italic> = 0.031), and 11 patients in the AT<sub>1</sub>R group and 12 in the non-AT<sub>1</sub>R group experienced myocardial infarction (<italic>P</italic> = 0.042). This resulted in a significantly lower overall arterial thrombotic event rate in the AT<sub>1</sub>R group compared with that in the non-AT<sub>1</sub>R group (<italic>P</italic> = 0.002) [<xref ref-type="table" rid="T3">Table 3</xref>].</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Comparison of thrombotic event rate during follow-up (<italic>n</italic> (%))</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variables</th><th align="center" valign="top" rowspan="1" colspan="1">AT<sub>1</sub>R group (<italic>n</italic> = 140)</th><th align="center" valign="top" rowspan="1" colspan="1">Non-AT<sub>1</sub>R group (<italic>n</italic> = 70)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Brain infarction</td><td align="center" rowspan="1" colspan="1">9 (6.43)</td><td align="center" rowspan="1" colspan="1">11 (15.71)</td><td align="center" rowspan="1" colspan="1">0.031</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarction</td><td align="center" rowspan="1" colspan="1">11 (7.86)</td><td align="center" rowspan="1" colspan="1">12 (17.14)</td><td align="center" rowspan="1" colspan="1">0.042</td></tr><tr><td align="left" rowspan="1" colspan="1">Overall thrombotic events</td><td align="center" rowspan="1" colspan="1">20 (14.3)</td><td align="center" rowspan="1" colspan="1">23 (32.8)</td><td align="center" rowspan="1" colspan="1">0.002</td></tr></tbody></table><table-wrap-foot><fn><p>AT<sub>1</sub>R: Angiotensin type 1 receptor.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-11"><title>Angiotensin II up-regulated expression of cyclooxygenase-2 via phosphorylation of p38 mitogen-activated protein kinase and nuclear factor-kB in human aortic endothelial cells</title><p>The expression of COX-2 mRNA in HCACEs was dose-and time-dependently increased after stimulation with Ang II, with maximum expression (4 times higher than control, <italic>P</italic> &#x0003c; 0.001) 1 h after stimulation with Ang II (100 nmol/L) [Figure <xref ref-type="fig" rid="F2">2a</xref> and <xref ref-type="fig" rid="F2">2b</xref>]. At protein level, the peak expression of COX-2 occurred 2 hours after Ang II stimulation (100 nmol/L) [<xref ref-type="fig" rid="F2">Figure 2c</xref>]. Ang II also increased the phosphorylation of p38MAPK (p-p38MAPK) and NF-kB (p-NF-kB) [<xref ref-type="fig" rid="F2">Figure 2d</xref>]; when pretreating HAECs with p38MAPK inhibitor SB203580 (25 &#x000b5;mol/L) and NF-kB inhibitor JSH-23 (25 &#x000b5;mol/L), the expression of COX-2 was significantly decreased at both mRNA and protein levels [Figure <xref ref-type="fig" rid="F2">2e</xref> and <xref ref-type="fig" rid="F2">f</xref>].</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Angiotensin II (Ang II) induced the expression of cyclooxygenase-2 (COX-2) and phosphorylation of p38 mitogen-activated protein kinase (p38MAPK) and nuclear factor-kB (NF-kB) in human aortic endothelial cells. (a) mRNA expression of COX-2 according to the concentration of Ang II. *<italic>P</italic> &#x0003c; 0.01. NS: not significant. (b) mRNA expression of COX-2 according to the time induced by Ang II (100 nmol/L). *<italic>P</italic> &#x0003c; 0.01 vs. control. <sup>&#x02020;</sup><italic>P</italic> &#x0003c; 0.001 vs. control. (c) Protein expression of COX-2 induced by Ang II (100 nmol/L). (d) Protein expression of p38 mitogen-activated protein kinase (p38MAPK), phosphorylation of p38MAPK, NF-kB and phosphorylation of NF-kB induced by Ang II. (e) The effect of SB203580 (25 nmol/L) and JSH-23 (25 nmol/L) on COX-2 mRNA expression induced by Ang II for 1 h; <sup>&#x02020;</sup><italic>P</italic> &#x0003c; 0.001. (f) The effect of SB203580 (25 nmol/L) and JSH-23 (25 nmol/L) on COX-2 protein expression induced by Ang II for 2 h. C means control group, SB + Ang means SB203580 + Ang II group, JSH + Ang means JSH-23 + Ang II group. Data represent the mean &#x000b1; standard deviation (<italic>n</italic> = 3).</p></caption><graphic xlink:href="CMJ-128-153-g002"/></fig></sec><sec id="sec2-12"><title>Cyclooxygenase-2 inhibitor suppressed angiotensin II-induced secretion of thromboxane B2 in human aortic endothelial cells</title><p>Ang II (100 nmol/L) led to a rapid increased secretion of TXB<sub>2</sub> in HAECs with peak secretion of 122.09 pg/ml at 3 h after its stimulation (4.47 times compared with 0 h, <italic>P</italic> &#x0003c; 0.001) [<xref ref-type="fig" rid="F3">Figure 3a</xref>] and this effect could be suppressed by COX-2 specific inhibitor NS-398 (<italic>P</italic> &#x0003c; 0.001) [<xref ref-type="fig" rid="F3">Figure 3b</xref>].</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Angiotensin II (Ang II) induced the expression of thromboxane B<sub>2</sub> (TXB<sub>2</sub>) in human aortic endothelial cells (HAECs). (a) Ang II's effect on TXB<sub>2</sub> expression; *<italic>P</italic> &#x0003c; 0.001 vs. 0 h. (b) HAECs were pretreated with NS-398 (2.5 &#x003bc;mol/L) and then incubated by Ang II for 3 h. *<italic>P</italic> &#x0003c; 0.001. Data represent the mean &#x000b1; standard deviation (<italic>n</italic> = 3).</p></caption><graphic xlink:href="CMJ-128-153-g003"/></fig></sec><sec id="sec2-13"><title>Valsartan decreased phosphorylation of p38 mitogen-activated protein kinase and nuclear factor-kB, as well as expression of cyclooxygenase-2 induced by angiotensin II in human aortic endothelial cells</title><p>After pretreatment with valsartan (100 nmol/L), HAECs were stimulated with Ang II (100 nmol/L) for 10 min to detect the p-p38MAPK and p-NF-kB, 1 h to detect COX-2 mRNA and 3 h to detect COX-2 protein. Valsartan (100 nmol/L) significantly inhibited Ang II-induced COX-2 mRNA and protein expression (<italic>P</italic> &#x0003c; 0.001) [Figure <xref ref-type="fig" rid="F4">4a</xref> and <xref ref-type="fig" rid="F4">4b</xref>], with parallel decrease in p-p38MAPK and p-NF-kB [<xref ref-type="fig" rid="F4">Figure 4c</xref>].</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Valsartan inhibited angiotensin II (Ang II) induced cyclooxygenase-2 (COX-2) and phosphorylation of p38 mitogen-activated protein kinase (p38MAPK)/nuclear factor-kB in human aortic endothelial cells. (a) Valsartan's effect on COX-2 mRNA expression induced by Ang II (100 nmol/L); *<italic>P</italic> &#x0003c; 0.01. (b) Valsartan's (100 nmol/L) effect on COX-2 protein expression induced by Ang II (100 nmol/L); (c) Valsartan's (100 nmol/L) effect on p38 mitogen-activated protein kinase (p38MAPK), phosphorylation of p38MAPK, phosphorylation of nuclear factor-kB (NF-kB), NF-kB expression induced by Ang II (100 nmol/L). C means control group, Ang means Ang II group, Val + Ang means Valsartan + Ang II group. Data represent the mean &#x000b1; standard deviation (<italic>n</italic> = 3).</p></caption><graphic xlink:href="CMJ-128-153-g004"/></fig></sec></sec><sec sec-type="discussion" id="sec1-4"><title>D<sc>ISCUSSION</sc></title><p>This randomized trial demonstrates that AT<sub>1</sub>R antagonist valsartan reduces cardio-cerebral thrombotic events in elderly patients with hypertension, by inhibiting platelet activity through attenuating Ang II-induced COX-2/TXA<sub>2</sub> expression via p38MAPK and NF-kB pathways.</p><p>The results of this study show that platelet aggregation induced by arachidonic acids and plasma levels of COX-2 and TXA<sub>2</sub> were elevated in elderly hypertensive patients. Although the majority of these patients were receiving anti-platelet therapy, around 20% of them still developed brain or myocardial infarction during follow-up. This is consistent with previous reports that elderly hypertensive patients are at high risk for cardio-cerebral vascular thrombosis.[<xref rid="ref18" ref-type="bibr">18</xref>] Interestingly, anti-hypertensive treatment with valsartan inhibits platelets activity and is associated with a lower rate of brain infarction in the AT<sub>1</sub>R group. The nonsignificant decrease in the occurrence of myocardial infarction after valsartan treatment may be, at least partly, due to a smaller number of study patients and a shorter period of follow-up for addressing such an outcome issue. Nevertheless, our observations substantiate a notion that AT<sub>1</sub>R antagonists exert a beneficial effect on the prevention of cardio-cerebral thrombotic events in elderly patients with hypertension.</p><p>It is well-recognized that Ang II regulates vascular structure and function and participates in the inflammatory response in vascular tissue.[<xref rid="ref19" ref-type="bibr">19</xref>] <italic>In vitro</italic> experiments demonstrated that Ang II stimulation significantly increases platelet-free calcium concentration, intracellular pH, and thrombin-induced platelet aggregation.[<xref rid="ref20" ref-type="bibr">20</xref>] Animal models have shown that this molecule increases platelet activity and accelerates microvascular thrombosis, whereas these processes are suppressed in AT<sub>1</sub>R deficient mice.[<xref rid="ref21" ref-type="bibr">21</xref>] Similar to the findings in vascular smooth muscle cells and aortic fibroblasts,[<xref rid="ref22" ref-type="bibr">22</xref>] we found that Ang II up-regulates the expression of COX-2 in human endothelial cells, which subsequently catalyzes arachidonic acid into prostaglandin and leads to an increased level of TXA<sub>2</sub>. These observations suggest that AT<sub>1</sub>R antagonists may retard the process of thrombus formation by inhibiting platelet aggregation.[<xref rid="ref23" ref-type="bibr">23</xref>]</p><p>Our <italic>in vitro</italic> study indicates that the effect of Ang II on the expression of COX-2 was at least partially through the modulation of p38MAPK and NF-kB pathways. The activity of transcription factor NF-kB is a hallmark of cellular inflammation response and has already been demonstrated in the expression of VCAM-1 regulated by ROS induced by Ang II.[<xref rid="ref24" ref-type="bibr">24</xref><xref rid="ref25" ref-type="bibr">25</xref>] However, the role of classic G protein, receptor tyrosine kinases (EGFR, platelet-derived growth factor and insulin receptor), NADPH oxidases and serine/threonine kinases such as PKC and MAPKs (JNK and p42/44MAPK) in the action of Ang II need further studies.[<xref rid="ref25" ref-type="bibr">25</xref><xref rid="ref26" ref-type="bibr">26</xref>]</p><p>We recognized several limitations in the present study. First, the number of patients in this study had insufficient power to detect the difference in terms of clinical outcome, thus further prospective studies with larger sample size are needed to confirm the beneficial effects of AT<sub>1</sub>R antagonists in the antithrombotic treatment of elderly hypertensive patients. Second, we could not completely eliminate the effect of other factors on the platelets activity, such as coronary artery disease and diabetes, which are common co-morbidities in these patients.</p></sec></body><back><fn-group><fn fn-type="edited-by"><p><bold>Edited by:</bold> Yuan-yuan Ji</p></fn><fn fn-type="supported-by"><p><bold>Source of Support:</bold> This work was supported by grants from the Shanghai Council for Science and Technology (No. 124119a6800), Shanghai Key Discipline of Public Health Building Program (No. 12GWEX1002) and National Clinical Key Specialty Construction Projects Funding.</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>R<sc>EFERENCES</sc></title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchesi</surname><given-names>C</given-names></name><name><surname>Paradis</surname><given-names>P</given-names></name><name><surname>Schiffrin</surname><given-names>EL</given-names></name></person-group><article-title>Role of the renin-angiotensin system in vascular inflammation</article-title><source>Trends Pharmacol Sci</source><year>2008</year><volume>29</volume><fpage>367</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">18579222</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tocci</surname><given-names>G</given-names></name><name><surname>Castello</surname><given-names>L</given-names></name><name><surname>Volpe</surname><given-names>M</given-names></name></person-group><article-title>A review of angiotensin receptor blocker-based therapies at all levels of cardiovascular risk</article-title><source>Eur Cardiol Rev</source><year>2011</year><volume>7</volume><fpage>254</fpage><lpage>56</lpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrin</surname><given-names>M</given-names></name><name><surname>Mazzolai</surname><given-names>L</given-names></name></person-group><article-title>Angiotensin ii as an inducer of atherosclerosis: Evidence from mouse studies</article-title><source>J Clin Exp Cardiol</source><year>2013</year><volume>S1</volume><fpage>2</fpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiffrin</surname><given-names>EL</given-names></name><name><surname>Park</surname><given-names>JB</given-names></name><name><surname>Intengan</surname><given-names>HD</given-names></name><name><surname>Touyz</surname><given-names>RM</given-names></name></person-group><article-title>Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>1653</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10758046</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duprez</surname><given-names>DA</given-names></name></person-group><article-title>Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: A clinical review</article-title><source>J Hypertens</source><year>2006</year><volume>24</volume><fpage>983</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">16685192</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balkrishnan</surname><given-names>R</given-names></name><name><surname>Phatak</surname><given-names>H</given-names></name><name><surname>Gleim</surname><given-names>G</given-names></name><name><surname>Karve</surname><given-names>S</given-names></name></person-group><article-title>Assessment of the use of angiotensin receptor blockers in major European markets among paediatric population for treating essential hypertension</article-title><source>J Hum Hypertens</source><year>2009</year><volume>23</volume><fpage>420</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">19052566</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>S</given-names></name><name><surname>Laury-Kleintop</surname><given-names>L</given-names></name><name><surname>Lanza-Jacoby</surname><given-names>S</given-names></name></person-group><article-title>The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice</article-title><source>J Surg Res</source><year>2008</year><volume>146</volume><fpage>135</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">17950326</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipollone</surname><given-names>F</given-names></name><name><surname>Fazia</surname><given-names>ML</given-names></name></person-group><article-title>COX-2 and atherosclerosis</article-title><source>J Cardiovasc Pharmacol</source><year>2006</year><volume>47</volume><issue>Suppl 1</issue><fpage>S26</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">16785826</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dav&#x000ec;</surname><given-names>G</given-names></name><name><surname>Patrono</surname><given-names>C</given-names></name></person-group><article-title>Platelet activation and atherothrombosis</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>2482</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">18077812</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YB</given-names></name><name><surname>Han</surname><given-names>JY</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Selenium inhibits high glucose-induced cyclooxygenase-2 and P-selectin expression in vascular endothelial cells</article-title><source>Mol Biol Rep</source><year>2011</year><volume>38</volume><fpage>2301</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">21052844</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briones</surname><given-names>AM</given-names></name><name><surname>Salaices</surname><given-names>M</given-names></name><name><surname>Vila</surname><given-names>E</given-names></name></person-group><article-title>Ageing alters the production of nitric oxide and prostanoids after IL-1beta exposure in mesenteric resistance arteries</article-title><source>Mech Ageing Dev</source><year>2005</year><volume>126</volume><fpage>710</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">15888326</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caughey</surname><given-names>GE</given-names></name><name><surname>Cleland</surname><given-names>LG</given-names></name><name><surname>Penglis</surname><given-names>PS</given-names></name><name><surname>Gamble</surname><given-names>JR</given-names></name><name><surname>James</surname><given-names>MJ</given-names></name></person-group><article-title>Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: Selective up-regulation of prostacyclin synthesis by COX-2</article-title><source>J Immunol</source><year>2001</year><volume>167</volume><fpage>2831</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11509629</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vane</surname><given-names>JR</given-names></name><name><surname>Bakhle</surname><given-names>YS</given-names></name><name><surname>Botting</surname><given-names>RM</given-names></name></person-group><article-title>Cyclooxygenases 1 and 2</article-title><source>Annu Rev Pharmacol Toxicol</source><year>1998</year><volume>38</volume><fpage>97</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">9597150</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chrysant</surname><given-names>SG</given-names></name><name><surname>Chrysant</surname><given-names>GS</given-names></name></person-group><article-title>The pleiotropic effects of angiotensin receptor blockers</article-title><source>J Clin Hypertens (Greenwich)</source><year>2006</year><volume>8</volume><fpage>261</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16596029</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chobanian</surname><given-names>AV</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><name><surname>Cushman</surname><given-names>WC</given-names></name><name><surname>Green</surname><given-names>LA</given-names></name><name><surname>Izzo</surname><given-names>JL</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</article-title><source>Hypertension</source><year>2003</year><volume>42</volume><fpage>1206</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">14656957</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasparyan</surname><given-names>AY</given-names></name><name><surname>Ayvazyan</surname><given-names>L</given-names></name><name><surname>Mikhailidis</surname><given-names>DP</given-names></name><name><surname>Kitas</surname><given-names>GD</given-names></name></person-group><article-title>Mean platelet volume: A link between thrombosis and inflammation?</article-title><source>Curr Pharm Des</source><year>2011</year><volume>17</volume><fpage>47</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">21247392</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>ZH</given-names></name><name><surname>Jiao</surname><given-names>JR</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Luo</surname><given-names>BY</given-names></name><name><surname>Wang</surname><given-names>XF</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name></person-group><article-title>Aspirin resistance: Clinical significance and genetic polymorphism</article-title><source>J Int Med Res</source><year>2012</year><volume>40</volume><fpage>282</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">22429367</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wing</surname><given-names>LM</given-names></name><name><surname>Reid</surname><given-names>CM</given-names></name><name><surname>Ryan</surname><given-names>P</given-names></name><name><surname>Beilin</surname><given-names>LJ</given-names></name><name><surname>Brown</surname><given-names>MA</given-names></name><name><surname>Jennings</surname><given-names>GL</given-names></name><etal/></person-group><article-title>A comparison of outcomes with angiotensin-converting &#x02013; enzyme inhibitors and diuretics for hypertension in the elderly</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>583</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">12584366</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Yin</surname><given-names>KS</given-names></name><name><surname>Liu</surname><given-names>KY</given-names></name><name><surname>Lu</surname><given-names>GJ</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Chen</surname><given-names>JD</given-names></name></person-group><article-title>Effect of valsartan on the expression of angiotensin II receptors in the lung of chronic antigen exposure rats</article-title><source>Chin Med J</source><year>2008</year><volume>121</volume><fpage>2312</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19080339</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Touyz</surname><given-names>RM</given-names></name><name><surname>Schiffrin</surname><given-names>EL</given-names></name></person-group><article-title>Effects of angiotensin II and endothelin-1 on platelet aggregation and cytosolic pH and free Ca2+concentrations in essential hypertension</article-title><source>Hypertension</source><year>1993</year><volume>22</volume><fpage>853</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">8244517</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senchenkova</surname><given-names>EY</given-names></name><name><surname>Russell</surname><given-names>J</given-names></name><name><surname>Almeida-Paula</surname><given-names>LD</given-names></name><name><surname>Harding</surname><given-names>JW</given-names></name><name><surname>Granger</surname><given-names>DN</given-names></name></person-group><article-title>Angiotensin II-mediated microvascular thrombosis</article-title><source>Hypertension</source><year>2010</year><volume>56</volume><fpage>1089</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">20975035</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beltr&#x000e1;n</surname><given-names>AE</given-names></name><name><surname>Briones</surname><given-names>AM</given-names></name><name><surname>Garc&#x000ed;a-Redondo</surname><given-names>AB</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>C</given-names></name><name><surname>Miguel</surname><given-names>M</given-names></name><name><surname>Alvarez</surname><given-names>Y</given-names></name><etal/></person-group><article-title>p38 MAPK contributes to angiotensin II-induced COX-2 expression in aortic fibroblasts from normotensive and hypertensive rats</article-title><source>J Hypertens</source><year>2009</year><volume>27</volume><fpage>142</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">19145780</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>YM</given-names></name><name><surname>Sharma</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>GP</given-names></name><name><surname>Zhao</surname><given-names>YN</given-names></name></person-group><article-title>Effect of angiotensin II type 1 receptor antagonist, losartan on inflamma-tory factor in atherosclerotic rabbits</article-title><source>Res Cardiovasc Med</source><year>2013</year><volume>1</volume><fpage>128</fpage><lpage>31</lpage></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>KK</given-names></name></person-group><article-title>Differential cyclooxygenase-2 transcriptional control in proliferating versus quiescent fibroblasts</article-title><source>Prostaglandins Other Lipid Mediat</source><year>2007</year><volume>83</volume><fpage>175</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">17481552</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>PK</given-names></name><name><surname>Griendling</surname><given-names>KK</given-names></name></person-group><article-title>Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system</article-title><source>Am J Physiol Cell Physiol</source><year>2007</year><volume>292</volume><fpage>C82</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">16870827</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>YY</given-names></name><name><surname>Guo</surname><given-names>XL</given-names></name><name><surname>Liu</surname><given-names>HG</given-names></name></person-group><article-title>Ang II type 1 receptor expression in rat aorta exposed to chronic intermittent hypoxia: Effects of p38MAPK and ERK1/2 signaling</article-title><source>Chin Med J</source><year>2013</year><volume>126</volume><fpage>3264</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24033947</pub-id></element-citation></ref></ref-list></back></article>